JP7157752B2 - Ag-10、その中間体及びその塩の調製方法 - Google Patents

Ag-10、その中間体及びその塩の調製方法 Download PDF

Info

Publication number
JP7157752B2
JP7157752B2 JP2019545281A JP2019545281A JP7157752B2 JP 7157752 B2 JP7157752 B2 JP 7157752B2 JP 2019545281 A JP2019545281 A JP 2019545281A JP 2019545281 A JP2019545281 A JP 2019545281A JP 7157752 B2 JP7157752 B2 JP 7157752B2
Authority
JP
Japan
Prior art keywords
formula
compound
crystalline form
organic solvent
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019545281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507618A5 (cg-RX-API-DMAC10.html
JP2020507618A (ja
Inventor
チャンド プーラン
クマー グプタ ヨーゲッシュ
クマー クマワット ラケシュ
アルハマドシェ ママウン
ザンボーニ ロバート
Original Assignee
エイドス セラピューティクス,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイドス セラピューティクス,インコーポレイティド filed Critical エイドス セラピューティクス,インコーポレイティド
Publication of JP2020507618A publication Critical patent/JP2020507618A/ja
Publication of JP2020507618A5 publication Critical patent/JP2020507618A5/ja
Priority to JP2022162530A priority Critical patent/JP2022183220A/ja
Application granted granted Critical
Publication of JP7157752B2 publication Critical patent/JP7157752B2/ja
Priority to JP2024178238A priority patent/JP2024177569A/ja
Priority to JP2026096470A priority patent/JP2026127822A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019545281A 2017-02-17 2018-02-16 Ag-10、その中間体及びその塩の調製方法 Active JP7157752B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022162530A JP2022183220A (ja) 2017-02-17 2022-10-07 Ag-10、その中間体及びその塩の調製方法
JP2024178238A JP2024177569A (ja) 2017-02-17 2024-10-10 Ag-10、その中間体及びその塩の調製方法
JP2026096470A JP2026127822A (ja) 2017-02-17 2026-06-09 Ag-10、その中間体及びその塩の調製方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762460576P 2017-02-17 2017-02-17
US62/460,576 2017-02-17
PCT/US2018/000025 WO2018151815A1 (en) 2017-02-17 2018-02-16 Processes for preparing ag-10, its intermediates, and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162530A Division JP2022183220A (ja) 2017-02-17 2022-10-07 Ag-10、その中間体及びその塩の調製方法

Publications (3)

Publication Number Publication Date
JP2020507618A JP2020507618A (ja) 2020-03-12
JP2020507618A5 JP2020507618A5 (cg-RX-API-DMAC10.html) 2021-03-25
JP7157752B2 true JP7157752B2 (ja) 2022-10-20

Family

ID=63166944

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019545281A Active JP7157752B2 (ja) 2017-02-17 2018-02-16 Ag-10、その中間体及びその塩の調製方法
JP2022162530A Pending JP2022183220A (ja) 2017-02-17 2022-10-07 Ag-10、その中間体及びその塩の調製方法
JP2024178238A Pending JP2024177569A (ja) 2017-02-17 2024-10-10 Ag-10、その中間体及びその塩の調製方法
JP2026096470A Pending JP2026127822A (ja) 2017-02-17 2026-06-09 Ag-10、その中間体及びその塩の調製方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022162530A Pending JP2022183220A (ja) 2017-02-17 2022-10-07 Ag-10、その中間体及びその塩の調製方法
JP2024178238A Pending JP2024177569A (ja) 2017-02-17 2024-10-10 Ag-10、その中間体及びその塩の調製方法
JP2026096470A Pending JP2026127822A (ja) 2017-02-17 2026-06-09 Ag-10、その中間体及びその塩の調製方法

Country Status (17)

Country Link
US (5) US10513497B2 (cg-RX-API-DMAC10.html)
EP (1) EP3582773A4 (cg-RX-API-DMAC10.html)
JP (4) JP7157752B2 (cg-RX-API-DMAC10.html)
KR (3) KR102665258B1 (cg-RX-API-DMAC10.html)
CN (2) CN116730920A (cg-RX-API-DMAC10.html)
AU (2) AU2018222739C1 (cg-RX-API-DMAC10.html)
CA (1) CA3051357A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019002321A1 (cg-RX-API-DMAC10.html)
EA (1) EA201991921A1 (cg-RX-API-DMAC10.html)
IL (3) IL268683B2 (cg-RX-API-DMAC10.html)
MA (1) MA47511A (cg-RX-API-DMAC10.html)
MX (3) MX388841B (cg-RX-API-DMAC10.html)
NZ (1) NZ755597A (cg-RX-API-DMAC10.html)
SG (1) SG11201906922TA (cg-RX-API-DMAC10.html)
TW (3) TWI849678B (cg-RX-API-DMAC10.html)
WO (1) WO2018151815A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202407964B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3582773A4 (en) 2017-02-17 2021-03-10 Eidos Therapeutics, Inc. PROCESS FOR THE MANUFACTURING OF AG-10, ITS INTERMEDIATES AND SALTS THEREOF
WO2019183463A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
WO2023009612A1 (en) 2021-07-28 2023-02-02 Protego Biopharma, Inc. Acoramidis (3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid) derivatives for stabilizing transthyretin (tts) and inhibiting tts misfolding for the treatment of e.g. peripheral ttr amyloidosis
WO2023052652A1 (en) 2021-10-01 2023-04-06 Sandoz Ag Crystalline form of acoramidis hydrochloride
WO2025220043A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Solid state forms of acoramidis and process for their preparation
WO2026050334A1 (en) 2024-08-29 2026-03-05 Alexion Pharmaceuticals, Inc. Transthyretin stabilizers and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ,インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JP2016504338A (ja) 2012-12-21 2016-02-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ トランスサイレチン安定剤並びにトランスサイレチン・アミロイドーシス及びタンパク質−タンパク質相互作用を抑制するためのそれらの使用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4255329A (en) 1973-10-02 1981-03-10 Syva Company Double receptor fluorescent immunoassay
US4117149A (en) 1975-09-12 1978-09-26 Pfizer Inc. 4-oxo-4h-benzopyrans as animal growth promotants
US4171365A (en) 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
US4261928A (en) 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4232161A (en) 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4234725A (en) 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4668640A (en) 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB2120242A (en) 1982-04-30 1983-11-30 Erba Farmitalia Ergoline derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4764521A (en) 1983-07-18 1988-08-16 Eli Lilly And Company Leukotriene antagonists and a method of use there as
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5315015A (en) 1992-11-10 1994-05-24 Hoffmann-La Roche Inc. Compounds having improved fluorescence in fluorescence polarization immunoassays and immunoassays utilizing same
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
HU224548B1 (hu) 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP2005513026A (ja) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環
PT1511710E (pt) 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
WO2004096808A1 (en) 2003-04-28 2004-11-11 De Novo Pharmaceuticals Limited Triazine compounds and their use
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006088694A1 (en) 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
WO2007012019A2 (en) 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
EA200900821A1 (ru) 2006-12-22 2010-02-26 Новартис Аг Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
BRPI0811446A2 (pt) 2007-05-11 2014-10-29 Lilly Co Eli " 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil pirazinas e piridinas e 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas de receptor 5-ht7"
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2(mglu2 수용체)의 포지티브 조절자로서의 헤테로사이클릭 화합물
ES2351274T3 (es) 2007-06-06 2011-02-02 Torrent Pharmaceuticals Ltd Nuevos compuestos.
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EA019033B1 (ru) 2008-03-26 2013-12-30 Новартис Аг Ингибиторы дезацетилазы в, основанные на гидроксамате
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2937418B1 (en) 2008-10-20 2017-10-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
EP2566333A4 (en) 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
CA2822039C (en) 2010-12-16 2019-05-28 Allergan, Inc. Sulfur derivatives as chemokine receptor modulators
US20160045609A1 (en) * 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
EP4233846B1 (en) 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
MX375424B (es) 2015-07-31 2025-03-06 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3582773A4 (en) 2017-02-17 2021-03-10 Eidos Therapeutics, Inc. PROCESS FOR THE MANUFACTURING OF AG-10, ITS INTERMEDIATES AND SALTS THEREOF
WO2019183463A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ,インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JP2016504338A (ja) 2012-12-21 2016-02-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ トランスサイレチン安定剤並びにトランスサイレチン・アミロイドーシス及びタンパク質−タンパク質相互作用を抑制するためのそれらの使用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BYRN S,PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS,PHARMACEUTICAL RESEARCH,米国,KLUWER ACADEMIC PUBLISHERS,1995年07月01日,V12 N7,P945-954
Penchala, Sravan C. et al,AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin,Proceedings of the National Academy of Sciences of the United States of America ,2013年,110(24),,9992-9997, S9992/1-S9992/23
PHARM STAGE,2007年,6,48-53
医薬審発第568号,2001年
有機合成化学協会誌,2007年,65,907-913
生活工学研究,2002年,4,310-317
高田則幸,創薬段階における原薬Formスクリーニングと選択,PHARM STAGE,Vol.6, No.10,2007年01月15日,p.20-25

Also Published As

Publication number Publication date
KR20240068787A (ko) 2024-05-17
CN116730921A (zh) 2023-09-12
US20200247756A1 (en) 2020-08-06
IL298196A (en) 2023-01-01
MA47511A (fr) 2019-12-25
US11078162B2 (en) 2021-08-03
ZA202407964B (en) 2025-05-28
IL268683B (en) 2022-12-01
CN110381940A (zh) 2019-10-25
US11919865B2 (en) 2024-03-05
WO2018151815A1 (en) 2018-08-23
JP2024177569A (ja) 2024-12-19
AU2018222739B2 (en) 2024-03-14
TW201835053A (zh) 2018-10-01
JP2026127822A (ja) 2026-08-06
AU2018222739C1 (en) 2024-10-03
CN116730920A (zh) 2023-09-12
BR112019016935A2 (pt) 2020-04-07
US20220041558A1 (en) 2022-02-10
US20240239751A1 (en) 2024-07-18
NZ797275A (en) 2026-01-30
CL2019002321A1 (es) 2019-12-27
TWI791487B (zh) 2023-02-11
KR20250151621A (ko) 2025-10-21
CA3051357A1 (en) 2018-08-23
CN110381940B (zh) 2023-07-21
NZ755597A (en) 2023-06-30
TWI849678B (zh) 2024-07-21
IL320441A (en) 2025-06-01
JP2020507618A (ja) 2020-03-12
NZ797281A (en) 2025-10-31
MX2022015151A (es) 2023-02-01
TW202342430A (zh) 2023-11-01
AU2024204057A1 (en) 2024-07-04
AU2018222739A1 (en) 2019-08-22
US20250313534A1 (en) 2025-10-09
EA201991921A1 (ru) 2020-02-06
SG11201906922TA (en) 2019-09-27
TW202515849A (zh) 2025-04-16
MX388841B (es) 2025-03-20
MX2021015220A (es) 2022-12-01
US20180237396A1 (en) 2018-08-23
US10513497B2 (en) 2019-12-24
KR102665258B1 (ko) 2024-05-10
KR20190130128A (ko) 2019-11-21
IL268683B2 (en) 2023-04-01
EP3582773A4 (en) 2021-03-10
IL268683A (en) 2019-10-31
KR102874295B1 (ko) 2025-10-20
JP2022183220A (ja) 2022-12-08
MX2019009764A (es) 2019-11-11
EP3582773A1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
JP2022183220A (ja) Ag-10、その中間体及びその塩の調製方法
JP6873053B2 (ja) タンパク質脱アセチル化阻害剤の製造方法
US20190211008A1 (en) Solid state forms of palbociclib dimesylate
AU2021201177B2 (en) Processes for preparing an FGFR inhibitor
EA050035B1 (ru) Способы получения ag-10, его промежуточных соединений и их солей
HK40098884A (en) Processes for preparing ag-10, its intermediates, and salts thereof
HK40098883A (en) Processes for preparing ag-10, its intermediates, and salts thereof
EA041474B1 (ru) Способы получения ag-10, его промежуточных соединений и их солей
BR112019016935B1 (pt) Formas cristalinas, seus usos, seus métodos de preparação, e composição
BR122025006893A2 (pt) Compostos cristalinos de ag-10, método para a preparação dos mesmos e sais farmaceuticamente aceitáveis de seus intermediários
WO2025186427A1 (en) Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib
BR122025006893B1 (pt) Sal farmaceuticamente aceitável e intermediários de ag-10

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221007

R150 Certificate of patent or registration of utility model

Ref document number: 7157752

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250